We assessed the association of persistent low-level viraemia between 50–199 copies/ml (LLV) with the risk of virological failure (VF) among HIV-1-infected patients receiving combination antiretroviral therapy (ART).
Methods
ART-naive and ART-experienced patients followed up in the ANRS-CO3 Aquitaine Cohort were included if they started two nucleoside reverse transcriptase inhibitors (NRTIs) with either one non-nucleoside reverse transcriptase inhibitor (NNRTI) or one protease inhibitor boosted with ritonavir (PI/r) between 2000 and 2011 and achieved viral load (VL)<200 copies/ml 4–8 months after initiating ART. VF was defined as either two consecutive VL≥200 copies/ml or one VL≥200 followed by a modification of ART. LLV was defined as at least two consecutive VLs between 50–199 copies/ml for at least one month. We used Cox models to estimate the association of LLV with VF.
Results
Among 2,374 patients with a median follow-up of 3 years, 205 (8.6%) experienced LLV. LLV was strongly associated with further VF (adjusted hazard ratio [aHR] 2.30, 95% CI 1.65, 3.20). LLV was associated with VF in ART-experienced patients (aHR 3.02, 95% CI 2.10, 4.33) but not in ART-naive patients. Neither type of ART regimen (PI/r- versus NNRTI-based regimen) nor cumulative duration of LLV was associated with VF.
Conclusions
Persistent LLV between 50–199 copies/ml was associated with VF among ART-experienced patients under ART. LLV between 50–199 copies/ml in ART-experienced patients should lead, after assessing patient's adherence and checking for drug interactions, to a closer monitoring and to consider ART optimization.
References
1.
GünthardH.F., AbergJ.A., EronJ.J.Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.JAMA2014; 312: 410–425.
2.
CohenC.Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen.HIV Clin Trials2009; 10: 116–124.
3.
García-GascóP., MaidaI., BlancoF.Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome.J Antimicrob Chemother2008; 61: 699–704.
4.
GreubG., Cozzi-LepriA., LedergerberB.Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.AIDS2002; 16: 1967–1969.
5.
LapriseC., de PokomandyA., BarilJ.G., DufresneS., TrottierH.Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.Clin Infect Dis2013; 57: 1489–1496.
6.
GerettiA.M., SmithC., HaberlA.Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.Antivir Ther2008; 13: 927–936.
7.
SungkanuparphS., GrogerR.K., OvertonE.T., FraserV.J., PowderlyW.G.Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy.HIV Med2006; 7: 437–441.
8.
ThiébautR., MorlatP., Jacqmin-GaddaH.Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidemiologie du SIDA en Aquitaine (GECSA).AIDS2000; 14: 971–978.
9.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services (Updated 13 November 2014. Accessed 16 November 2014.) Available from http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
10.
VandenhendeM., IngleS., MayM.Impact of low-level viremia on clinical and virological outcomes in treated HIV-1 infected patients.AIDS2015; 29: 373–383.
11.
DelaugerreC., GallienS., FlandreP.Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.PLoS ONE2012; 7: e36673.
12.
SwensonL.C., MinJ.E., WoodsC.K.HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.AIDS2014; 28: 1125–1134.
13.
TaiwoB., GallienS., AgaE.Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.J Infect Dis2011; 204: 515–520.
14.
CorbeauP., ReynesJ.Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection.Blood2011; 117: 5582–5590.
15.
RamratnamB., MittlerJ.E., ZhangL.The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.Nat Med2000; 6: 82–85.
16.
HuntP.W.HIV and inflammation: mechanisms and consequences.Curr HIV/AIDS Rep2012; 9: 139–147.
